A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer
The present study aims to investigate the efficacy and safety of the combination of capecitabine and gemcitabine in heavily pre-treated, treatment resistant metastatic colorectal cancer.
Metastatic Colorectal Cancer
DRUG: Gemcitabine + Capecitabine
Rate of patients progression free at 3 months, 3 months after start of treatment
Progression free survival, Every 12 weeks|Overall survival, Every 12 weeks
The present study aims to investigate the efficacy and safety of the combination of capecitabine and gemcitabine in heavily pre-treated, treatment resistant metastatic colorectal cancer.